☆ 4.3 Article

Comparison of ticagrelor and clopidogrel on platelet function and prognosis in unstable angina

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Geriatrics & Gerontology

Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study

Suining Xu et al.

Summary: This study found that ticagrelor was associated with a lower incidence of major adverse cardiovascular events than clopidogrel at 12 months in elderly Chinese patients with coronary artery disease, without a significant increase of bleeding events.

DRUGS & AGING (2022)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy and Safety of Ticagrelor vs. Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study

Chi-Jen Chang et al.

Summary: The study compared the efficacy and safety of ticagrelor vs. clopidogrel in East Asian patients with acute myocardial infarction. Ticagrelor was found comparable to clopidogrel in terms of the composite of death, MI, and stroke, but had a higher risk of bleeding.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Loading doses of ticagrelor versus clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome

Ya-Ru Zhang et al.

Summary: This study compared the safety and efficacy of ticagrelor and clopidogrel in preventing periprocedural myocardial infarction in Asian patients with acute coronary syndrome. The results showed a significantly lower incidence of periprocedural myocardial infarction and numerically lower bleeding events in the ticagrelor group compared to the clopidogrel group.

PERFUSION-UK (2021)

Add to Collection

Article Cell Biology

Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis

Mohitosh Biswas et al.

Summary: For ACS patients with CYP2C19 loss-of-function alleles undergoing PCI, alternative antiplatelets like prasugrel or ticagrelor may offer better efficacy and safety outcomes compared to clopidogrel.

PLATELETS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Ticagrelor versus clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial

Michalis Hamilos et al.

Summary: In STEMI patients undergoing thrombolysis, there was no significant difference in coronary microvascular function between clopidogrel and ticagrelor, and no significant differences were observed in major clinical events and major bleeding events between the two groups.

EUROINTERVENTION (2021)

Add to Collection

Article Peripheral Vascular Disease

Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Jianan Li et al.

Summary: This study compared the efficacy and safety of ticagrelor and clopidogrel in patients with SCAD undergoing PCI, and found that ticagrelor was associated with a lower incidence of MACCEs without an increased risk of bleeding events. Additionally, ticagrelor was shown to be superior to clopidogrel in terms of net adverse clinical events in this patient population.

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2021)

Add to Collection

Article Multidisciplinary Sciences

Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis

Thibault Charpentier et al.

PLOS ONE (2020)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Clopidogrel is a favourable alternative to ticagrelor in older patients with NSTE-ACS

Karina Huynh

NATURE REVIEWS CARDIOLOGY (2020)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Real-World Comparison of Ticagrelor and Clopidogrel: Rosetta Stone or Lost in Translation?

Brian A. Bergmark

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients

Mina W. Mohareb et al.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2020)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches

Ying Xue et al.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention

Jianan Li et al.

CURRENT MEDICAL RESEARCH AND OPINION (2020)

Add to Collection

Article Hematology

Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes

Zhenyu Liu et al.

THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Medicine, General & Internal

Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial

Marieke E. Gimbel et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Clinical Neurology

Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter/disrupter: A matched-cohort study comparing Cclopidogrel with ticagrelor>

Sebastien Soize et al.

JOURNAL OF NEURORADIOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

S. Schuepke et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients

Yang Sun et al.

ATHEROSCLEROSIS (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Antiplatelet effects of ticagrelor versus clopidogrel after coronary artery bypass graft surgery: A single-center randomized controlled trial

Fei Xu et al.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery

Juan J. Russo et al.

EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Thor Ueland et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study

Emil Hagstrom et al.

EUROPEAN HEART JOURNAL (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Yuichi J. Shimada et al.

AMERICAN HEART JOURNAL (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.